Navigation Links
Audentes Therapeutics to Present at the ARM 5th Annual Cell & Gene Therapy Investor Day
Date:4/17/2017

SAN FRANCISCO, April 17, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R. Patterson, President and Chief Executive Officer, will present a corporate overview at the Alliance for Regenerative Medicine's 5th Annual Cell & Gene Therapy Investor Day in Boston, MA.  The presentation is scheduled for Thursday, April 27, 2017, at 9:55 am ET.

To access a live webcast of the presentation, please visit the Events & Presentations page within the Investors & News section of the Audentes website.  Replays of live webcasts will be available on the Audentes website for approximately 30 days following the conference.

About Audentes Therapeutics, Inc.

Audentes Therapeutics (Nasdaq: BOLD) is a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases.  We have four product candidates in development, AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT342 for the treatment of Crigler-Najjar Syndrome, AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).  We are a focused, experienced and passionate team committed to forging strong, global relationships with the patient, research and medical communities.

For more information regarding Audentes, please visit www.audentestx.com.

Audentes Contacts:
Investor Contact:
Thomas Soloway, CFO
415.818.1040
ir@audentestx.com

Media Contact:
Jeffrey Gruis
415.818.1015
media@audentestx.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/audentes-therapeutics-to-present-at-the-arm-5th-annual-cell--gene-therapy-investor-day-300440070.html


'/>"/>
SOURCE Audentes Therapeutics, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Audentes Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
2. Amarantus Forms Subsidiaries "Elto Pharma" to Focus on CNS Disorders and "MANF Therapeutics" to Focus on Ophthalmology
3. Nektar Therapeutics Presents New Preclinical Data for its Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting
4. United Therapeutics Announces Decision From Patent Trial And Appeal Board And Issuance Of New Patents
5. Viking Therapeutics to Present at H.C. Wainwright & Co.s 1st Annual NASH Investor Conference
6. Biotech Stocks on Investors Radar -- Portola Pharma, OvaScience, Ocera Therapeutics, and Ocular Therapeutix
7. Leading Alzheimer’s Expert Joins T3D Therapeutics’ Advisory Board
8. Biotech Stocks Under Scanner -- BioDelivery Sciences, Sage Therapeutics, Benitec Biopharma, and OncoGenex Pharma
9. Oramed to Present at Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference on March 28, 2017
10. FACIT Announces Investment in Propellon Therapeutics
11. Avexegen Therapeutics Announces Exclusive License Agreement with Children’s Hospital Los Angeles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... 2017 Spectrecology LLC has announced a 4 ... and research dollars. The program is designed to help ... spectroscopy and photonics equipment despite current funding challenges.  The ... Innovations in Spectroscopy Grants – Discounts ... used for the classroom or research. ...
(Date:6/28/2017)... (PRWEB) , ... June 28, ... ... Siemens’ STAR-CCM+® software for multiphysics computational fluid dynamics (CFD) simulation and analysis ... and optimization. STAR-CCM+ version 12.04 introduces Design Manager, allowing users to easily ...
(Date:6/27/2017)... ... June 27, 2017 , ... Biodex Medical Systems, Inc. announces ... in one device. This assistive aid lifts patients safely from a seated to a ... lift mechanics. The Mobility Assist is the latest in a line of Biodex products ...
(Date:6/26/2017)... ... ... Third Wave Bioactives, LLC announces the addition of Brett Thompson. Brett joins ... and ensuring quality customer experience. , Brett brings to Third Wave Bioactives ... and sales roles. “Brett’s background working with customers and eye for market opportunities make ...
Breaking Biology Technology:
(Date:4/11/2017)... GARDENS, Fla. , April 11, 2017 /PRNewswire/ ... management and secure authentication solutions, today announced that ... by Intelligence Advanced Research Projects Activity (IARPA) to ... IARPA,s Thor program. "Innovation has been ... and IARPA,s Thor program will allow us to ...
(Date:4/11/2017)... BROOKLYN, N.Y. , April 11, 2017 /PRNewswire-USNewswire/ ... identical fingerprints, but researchers at the New York ... University College of Engineering have found that partial ... fingerprint-based security systems used in mobile phones and ... previously thought. The vulnerability lies in ...
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
Breaking Biology News(10 mins):